F-Genotype Mumps Vaccine Strain via SH Gene Deletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mumps vaccines are ineffective against non-A genotypes, particularly the dominant F genotype in China, and traditional weakening methods are inefficient and lack a clear mechanism, leading to long development cycles and safety concerns.
Innovation Solution
A reverse genetic operation technology is used to delete the SH gene in the F genotype mumps virus, creating an attenuated strain with clear weakening mechanism, suitable for large-scale production in primary chicken embryo fibroblasts, ensuring high safety and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional continuous passage weakening method is used, then the virus can be weakened, but the success rate is low and the development cycle is very long
Solution Approach 1:
The patent extracts and removes the SH gene from the mumps virus genome through reverse genetic technology. This specific gene extraction approach directly achieves virus attenuation without requiring lengthy continuous passage, thereby improving both the success rate of weakening and significantly shortening the development cycle compared to traditional methods
Solution Approach 2:
The patent performs preliminary genetic modification by deleting the SH gene before vaccine production. This preliminary action of targeted gene deletion establishes the attenuated phenotype in advance, eliminating the need for prolonged passage and evaluation periods required by traditional weakening methods
2Reliability
If traditional continuous passage weakening method is used, then the virus can be weakened, but the endpoint is not easy to judge and safety cannot be ensured
Solution Approach 1:
The patent replaces the empirical, observation-based traditional weakening method with a precise molecular biology approach. By using reverse genetic technology to specifically delete the SH gene, the weakening mechanism becomes scientifically defined and measurable through molecular detection, making the endpoint judgment objective and reliable
Solution Approach 2:
The patent changes the fundamental parameter of virus attenuation from gradual phenotypic change through passage to a specific genetic modification (SH gene deletion). This parameter change allows for precise detection and measurement of the attenuated state through genetic analysis, eliminating the difficulty of judging weakening endpoints
3Reliability
If A genotype vaccine is used, then it can protect against A genotype, but it cannot provide complete cross-protection against non-A genotypes including F genotype
Solution Approach 1:
The patent applies local quality by creating a vaccine specifically adapted to the F genotype virus structure and characteristics. By using F genotype virus as the basis for attenuation and deleting its specific SH gene, the vaccine achieves local optimization for F genotype protection, thereby improving cross-protection efficacy against circulating strains while maintaining genotype-specific adaptability
Data Source
AI summary
Provided are an F-genotype mumps virus attenuated strain, a construction method therefor and an application thereof. The attenuated strain is a mumps virus with the accession number of CCTCC NO: V201950. Further provided are a vaccine composition containing the F-genotype mumps virus attenuated strain as an active ingredient and a preparation method thereof.